Abstract 2117P
Background
The provision of nutrients in adequate quantity and quality is essential for the treatment of low muscle mass, which is highly found in patients with lung cancer (LC). Identifying an early deficit in food consumption is recommended as a strategy to preserve muscle and weight compartments that directly impact treatment tolerance, functionality and quality of life. This study aimed to investigate whether caloric and protein intake at diagnosis are predictive of outcomes in patients with LC.
Methods
This is a prospective, observational study. Data were collected at the first nutritional consultation between January and December 2019 and consisted of nutritional risk screening for cancer patients, height, body weight, weight loss, calf circumference, handgrip strength measured using a dynamometer and 24-hour recall to estimate average food and macronutrient intake. Survival curves were generated by Kaplan-Meier analysis to assess the association between caloric and protein intake and 3-year mortality.
Results
A total of 50 patients with LC were included, 62% were female, 94% elderly, 88% with non-small cell lung cancer, 88% were diagnosed with disease stages III and IV, and 64% were smokers. Weight-adjusted mean daily intake of energy was 18.6 kcal/kg/day and protein 0.94g/kg/day, and 86% and 60% had lower energy and protein intakes, respectively, than the recommended for patients with cancer. Individuals with consumption greater than 1g/kg/day had significantly longer overall survival with 35,2 versus 21,9 months than those with consumption lower than the recommendation for patients with cancer (p=0.03). There was no statistical difference according to the caloric intake (>25kcal/kg/day versus <25kcal/kg/day) (p=0.20).
Conclusions
Caloric and protein intake at diagnosis is low in patients with LC, and a lower protein intake was a predictor of negative results. Nutritional interventions are low-cost and can be easily implemented as a strategy to modify these results and improve care for these individuals.
Clinical trial identification
Research Ethics Committee approval CAAE: 19918319.1.0000.5533.
Editorial acknowledgement
Legal entity responsible for the study
Grupo Oncoclínicas / Federal University of Rio de Janeiro.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06
2106P - Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
Presenter: Amy Body
Session: Poster session 06
2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients
Presenter: Nikolaos Tsoukalas
Session: Poster session 06
2108P - Vitamin B12 and its clinical relevance in hospitalized cancer patients
Presenter: Stefano Maccarone
Session: Poster session 06
2109P - Vitamin A, D and E levels in patients with solid tumors undergoing palliative systemic cancer treatment
Presenter: Julia Berger
Session: Poster session 06
2111P - The value of multiple psychometric tools for distress screening and referral in a cancer population
Presenter: Daniel Anderson
Session: Poster session 06
2112P - Initial geriatric assessment and chemotherapy tolerability treatment in Brazilian patients with malignant neoplasm of the digestive system
Presenter: Marcos Dumont Bonfin Santos
Session: Poster session 06
2113P - Efficacy and effectiveness of prophylactic magnesium supplementation on prevention of cisplatin-induced nephrotoxicity: A systematic review and meta-analysis
Presenter: Caio Castro
Session: Poster session 06
2114P - Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Presenter: Jordi Recuero-Borau
Session: Poster session 06